Spontaneous Fusion with Transformed Mesenchymal Stromal Cells Results in Complete Heterogeneity in Prostate Cancer Cells
Wang R, Hu P, Wang F, Lyu J, Ou Y, Edderkaoui M, Zhang Y, Lewis M, Pandol S, Zhau H, Chung L. Spontaneous Fusion with Transformed Mesenchymal Stromal Cells Results in Complete Heterogeneity in Prostate Cancer Cells. Cancers 2024, 16: 951. PMID: 38473313, PMCID: PMC10931070, DOI: 10.3390/cancers16050951.Peer-Reviewed Original ResearchProstate cancer cellsStromal cell lineBystander cellsCancer cellsCell linesTumor cell heterogeneityFusion hybridsMesenchymal stromal cellsCell fusionTumor microenvironmentGenomic hybridizationTumor cellsMesenchymal stromal cell lineStromal cellsTumorDerivative clonesPhenotypic heterogeneityCell compartmentPhenotypic diversificationGenomic makeupBehavioral phenotypesCell heterogeneitySpontaneous fusionDerivative subclonesSublinesOvercoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate
Ou Y, Chu G, Lyu J, Yin L, Lim A, Zhai N, Cui X, Lewis M, Edderkaoui M, Pandol S, Wang R, Zhang Y. Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate. Molecular Pharmaceutics 2024, 21: 873-882. PMID: 38229228, PMCID: PMC11025579, DOI: 10.1021/acs.molpharmaceut.3c00993.Peer-Reviewed Original ResearchConceptsProstate cancerTherapeutic resistanceTarget PC cellsAndrogen receptor statusTraditional systemic treatmentsSuppressed xenograft tumor formationProstate cancer therapyCastration-resistant formTumor cell targetsPC cellsSignificant side effectsCancer-related deathsCell deathHeptamethine carbocyanine dyeXenograft tumor formationPC cell linesXenograft tumor modelReceptor statusHormone therapySystemic treatmentSafety profileTumor cellsChemotherapeutic drugsTumor modelCancer therapy